Xenotransplantation - Nuffield Council on Bioethics
Xenotransplantation - Nuffield Council on Bioethics
Xenotransplantation - Nuffield Council on Bioethics
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Animal-to-Human Transplants : the ethics of xenotransplantati<strong>on</strong><br />
Table 1.1<br />
One year and five year survival rates of<br />
transplant recipients 1<br />
Organ<br />
Survival Rates<br />
1 year 5 years<br />
Kidney 84% 70%<br />
Liver 62% 54%<br />
Heart 73% 62%<br />
1.4 Organ transplantati<strong>on</strong> offers several benefits. For some c<strong>on</strong>diti<strong>on</strong>s, such as advanced<br />
heart failure, treatment with drugs or restorative surgery may not be possible and a<br />
transplant will provide the <strong>on</strong>ly way of replacing a failed vital organ. Heart or liver<br />
transplantati<strong>on</strong> can offer many additi<strong>on</strong>al years of life for people who otherwise<br />
might not survive, as the <strong>on</strong>e year and five year survival rates for liver and heart<br />
transplant recipients show (Table 1.1). Worldwide there are patients whose lives have<br />
been c<strong>on</strong>siderably extended following transplantati<strong>on</strong>: by 23 years after liver<br />
transplants and 20 years after heart transplants.<br />
1.5 Transplantati<strong>on</strong> can not <strong>on</strong>ly increase the length of life, but also improve its quality.<br />
Even where there is an alternative form of treatment, such as dialysis for end-stage<br />
kidney failure, a transplant frequently offers a higher quality of life despite the<br />
drawbacks of the c<strong>on</strong>tinuous immunosuppressive regime most transplant recipients<br />
require. Kidney transplant recipients are freed from the necessity of regular,<br />
uncomfortable and time-c<strong>on</strong>suming treatment and are restored to a level of health not<br />
possible with dialysis. They are able to eat and drink freely, and to travel, in ways<br />
that people <strong>on</strong> l<strong>on</strong>g-term dialysis often cannot. Patient support groups describe heart<br />
transplant recipients who are able to climb hills, and undertake other activities, that<br />
they would not have been able to manage before the operati<strong>on</strong>. Some transplant<br />
recipients participate in highly demanding sporting c<strong>on</strong>tests such as the Transplant<br />
Games.<br />
1.6 It should be noted that, c<strong>on</strong>trary to some mispercepti<strong>on</strong>, transplantati<strong>on</strong> is not<br />
particularly expensive. Estimates are very difficult to make, but it is possible to get<br />
a rough idea of the relative costs of different treatments. A kidney transplant<br />
operati<strong>on</strong> costs in the regi<strong>on</strong> of £10,000. After that, the cost of immunosuppressive<br />
drugs and other follow-up treatment is about £3,000 a year. In c<strong>on</strong>trast, dialysis costs<br />
about £18,000 a year if the patient is treated in hospital, and about £11,000 if the<br />
patient is treated at home. Thus, kidney transplantati<strong>on</strong> is a more cost-effective<br />
1<br />
Source: United Kingdom Transplant Support Service Authority (UKTSSA) publicati<strong>on</strong>s: Renal Transplant<br />
Audit 1984-1993; Liver Transplant Audit 1985-1992; Thoracic Organ Transplant Audit 1985-1992.<br />
2